Absolute Bioavailability Study With Bexagliflozin

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 1, 2018

Primary Completion Date

September 16, 2018

Study Completion Date

September 16, 2018

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Bexagliflozin

Bexagliflozin tablets, 20 mg, and bexagliflozin by IV

Trial Locations (1)

53704

Clinical Research Site, Madison

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theracos

INDUSTRY

NCT03417076 - Absolute Bioavailability Study With Bexagliflozin | Biotech Hunter | Biotech Hunter